NERV
Minerva Neurosciences, Inc.·Healthcare
5.36
2.619%(+0.14)
Market OpenLast Updated: — ET
52W L: $1.4852W H: $12.46
NERV NEWS
zacks.com
May 20
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
Minerva Neurosciences (NERV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
May 20
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Minerva Neurosciences (NERV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
globenewswire.com
May 18
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
BURLINGTON, Mass. , May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman and Chief Executive Officer, will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.
globenewswire.com
May 18
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.
globenewswire.com
May 5
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug interaction concerns with roluperidone and olanzapine Roluperidone remains the only late-stage drug candidate for this high-need population BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported financial and business updates for the first quarter ended March 31, 2026.
defenseworld.net
Apr 13
Minerva Neurosciences, Inc (NASDAQ:NERV) Sees Significant Growth in Short Interest
Minerva Neurosciences, Inc (NASDAQ: NERV - Get Free Report) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totaling 1,020,925 shares, a growth of 82.5% from the March 15th total of 559,530 shares. Currently, 2.6% of the shares of the stock are short sold. Based
